BCL-xL and BAD, along with BCL-2, are upregulated in the majority of AML stem/progenitor cell populations, compared to normal hematopoietic stem/progenitor cells (HSPCs), with induction chemotherapy resulting in a further upregulation of BCL-2 and BCL-xL46,54. This evidence concerns the gene BCL2 and acute myeloid leukemia.